Skip to main content
Premium Trial:

Request an Annual Quote

Genomics England Establishes Partnership to Interpret Data from 100K Genomes Project

NEW YORK (GenomeWeb) – Genomics England today announced the Genomics England Clinical Interpretation Partnership (GeCIP) comprising about 2,000 researchers in 30 research topics connected to the 100,000 Genomes Project.

The researchers from academia and the UK National Health Service, as well as international collaborators, will conduct research in topics that mostly cover a single disease or group of diseases including cardiovascular disease, several cancers, health economics, population genomics, and translational research. 

Genomics England said that the work is anticipated to result in improved interpretation of genomic data, leading to better clinical insights and patient care. In a statement, Genomics England Chief Scientist Mark Caulfield said that the goal of GeCIP is to create a "powerful research and training program alongside the 100,000 Genomes Project … to ensure research findings go straight back to clinicians and patients so they can benefit."

Bill Newman, a professor at the University of Manchester and head of the validation and feedback group, added that the project "is very likely to identify changes in the genome that can cause disease, and these changes won't have been seen before."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more